Allarity Therapeutics Files 8-K
Ticker: ALLR · Form: 8-K · Filed: Sep 22, 2025 · CIK: 1860657
Sentiment: neutral
Topics: 8-k, filing, sec
TL;DR
Allarity Therapeutics filed an 8-K, check for updates.
AI Summary
On September 17, 2025, Allarity Therapeutics, Inc. filed an 8-K report. The filing primarily serves as a notification of other events and includes financial statements and exhibits. No specific material events or transactions were detailed in the provided excerpt.
Why It Matters
This filing indicates Allarity Therapeutics, Inc. is providing updates or submitting required documentation to the SEC, which could contain material information for investors.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for 'Other Events' and financial statements, with no immediate indication of significant positive or negative developments.
Key Players & Entities
- Allarity Therapeutics, Inc. (company) — Registrant
- September 17, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-41160 (other) — SEC File Number
- 123 E Tarpon Ave, Tarpon Springs, FL 34689 (address) — Principal executive offices
- 401-426-4664 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing for Allarity Therapeutics, Inc.?
The primary purpose of this 8-K filing is to report 'Other Events' and to include financial statements and exhibits as of September 17, 2025.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported is September 17, 2025.
In which state is Allarity Therapeutics, Inc. incorporated?
Allarity Therapeutics, Inc. is incorporated in Delaware.
What is the SEC file number for Allarity Therapeutics, Inc.?
The SEC file number for Allarity Therapeutics, Inc. is 001-41160.
What is the principal executive office address for Allarity Therapeutics, Inc.?
The principal executive office address is 123 E Tarpon Ave, Tarpon Springs, FL 34689.
Filing Stats: 444 words · 2 min read · ~1 pages · Grade level 10.5 · Accepted 2025-09-19 18:13:10
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share ALLR The Nasdaq Stock Mar
Filing Documents
- ea0258005-8k_allarity.htm (8-K) — 24KB
- ea025800501ex99-1_allarity.htm (EX-99.1) — 18KB
- ex99-1_001.jpg (GRAPHIC) — 9KB
- 0001213900-25-089680.txt ( ) — 220KB
- allr-20250917.xsd (EX-101.SCH) — 3KB
- allr-20250917_lab.xml (EX-101.LAB) — 33KB
- allr-20250917_pre.xml (EX-101.PRE) — 22KB
- ea0258005-8k_allarity_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. On September 17, 2025, Allarity Therapeutics, Inc. (the "Company") announced that its CEO, Mr. Thomas Jensen, has been invited to present at the upcoming Biomarkers & Precision Medicine 2025 conference in London, organized by Oxford Global. The Company's press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release, dated September 17, 2025 . 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Allarity Therapeutics, Inc. Date: September 19, 2025 By: /s/ Thomas H. Jensen Thomas H. Jensen Chief Executive Officer 2